Metastatic breast cancer

Tejal A. Patel, Edith A. Perez

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative. The average survival time after the diagnosis of metastatic breast cancer is 24 months, although it varies widely according to the metastatic site, biological characteristics, patient condition and treatment [1]. The median survival time traditionally has been lower for patients with visceral disease (6-13 months) compared with those with bone-only disease (18-30 months). There has been recent epidemiological data to suggest improvement in breast cancer mortality in the past 15 years in the United Kingdom and the United States [2]. One of the reports demonstrated that after adjustment of several factors, similar cohort of women diagnosed with metastatic breast cancer in late 1990s compared with early 1990s, had better survival by 30%.

Original languageEnglish (US)
Title of host publicationManagement of Breast Diseases
PublisherSpringer Berlin Heidelberg
Pages425-449
Number of pages25
ISBN (Print)9783540697428
DOIs
StatePublished - 2010

Fingerprint

Breast Neoplasms
Survival
Mortality
Bone Diseases
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Patel, T. A., & Perez, E. A. (2010). Metastatic breast cancer. In Management of Breast Diseases (pp. 425-449). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-69743-5_23

Metastatic breast cancer. / Patel, Tejal A.; Perez, Edith A.

Management of Breast Diseases. Springer Berlin Heidelberg, 2010. p. 425-449.

Research output: Chapter in Book/Report/Conference proceedingChapter

Patel, TA & Perez, EA 2010, Metastatic breast cancer. in Management of Breast Diseases. Springer Berlin Heidelberg, pp. 425-449. https://doi.org/10.1007/978-3-540-69743-5_23
Patel TA, Perez EA. Metastatic breast cancer. In Management of Breast Diseases. Springer Berlin Heidelberg. 2010. p. 425-449 https://doi.org/10.1007/978-3-540-69743-5_23
Patel, Tejal A. ; Perez, Edith A. / Metastatic breast cancer. Management of Breast Diseases. Springer Berlin Heidelberg, 2010. pp. 425-449
@inbook{e0935deb1c6b4eb0a605c419264180cd,
title = "Metastatic breast cancer",
abstract = "Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10{\%} of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative. The average survival time after the diagnosis of metastatic breast cancer is 24 months, although it varies widely according to the metastatic site, biological characteristics, patient condition and treatment [1]. The median survival time traditionally has been lower for patients with visceral disease (6-13 months) compared with those with bone-only disease (18-30 months). There has been recent epidemiological data to suggest improvement in breast cancer mortality in the past 15 years in the United Kingdom and the United States [2]. One of the reports demonstrated that after adjustment of several factors, similar cohort of women diagnosed with metastatic breast cancer in late 1990s compared with early 1990s, had better survival by 30{\%}.",
author = "Patel, {Tejal A.} and Perez, {Edith A.}",
year = "2010",
doi = "10.1007/978-3-540-69743-5_23",
language = "English (US)",
isbn = "9783540697428",
pages = "425--449",
booktitle = "Management of Breast Diseases",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Metastatic breast cancer

AU - Patel, Tejal A.

AU - Perez, Edith A.

PY - 2010

Y1 - 2010

N2 - Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative. The average survival time after the diagnosis of metastatic breast cancer is 24 months, although it varies widely according to the metastatic site, biological characteristics, patient condition and treatment [1]. The median survival time traditionally has been lower for patients with visceral disease (6-13 months) compared with those with bone-only disease (18-30 months). There has been recent epidemiological data to suggest improvement in breast cancer mortality in the past 15 years in the United Kingdom and the United States [2]. One of the reports demonstrated that after adjustment of several factors, similar cohort of women diagnosed with metastatic breast cancer in late 1990s compared with early 1990s, had better survival by 30%.

AB - Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative. The average survival time after the diagnosis of metastatic breast cancer is 24 months, although it varies widely according to the metastatic site, biological characteristics, patient condition and treatment [1]. The median survival time traditionally has been lower for patients with visceral disease (6-13 months) compared with those with bone-only disease (18-30 months). There has been recent epidemiological data to suggest improvement in breast cancer mortality in the past 15 years in the United Kingdom and the United States [2]. One of the reports demonstrated that after adjustment of several factors, similar cohort of women diagnosed with metastatic breast cancer in late 1990s compared with early 1990s, had better survival by 30%.

UR - http://www.scopus.com/inward/record.url?scp=84887914489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887914489&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-69743-5_23

DO - 10.1007/978-3-540-69743-5_23

M3 - Chapter

SN - 9783540697428

SP - 425

EP - 449

BT - Management of Breast Diseases

PB - Springer Berlin Heidelberg

ER -